Abstract
Cytochrome P450 (CYP) enzymes are a superfamily of heme containing proteins that catalyze xenobiotic metabolism phase I reactions. Oxidation reactions are the most common CYP-catalyzed reactions for both endogenous substrates and exogenous compounds, including drugs, although CYP enzymes are capable also to catalyze reduction reactions. Whereas the majority of clinically used drugs are inactivated by CYPs, several prodrugs are bioconverted to their active species by these enzymes. Therefore, this mechanism could be exploited to a greater extend, e.g. by taking advantage of the different CYP enzymes to achieve targeted drug delivery, to improve efficacy or to decrease the unwanted adverse effects of existing and novel drug molecules. This review describes the potential of CYP enzymes in prodrug design and summarizes a wide variety of CYP-activated prodrug structures, which are on the market or under the development. The bioactivation mechanisms of each CYP-activated prodrug structure are described and the specificity for the different forms of CYP enzymes is discussed.
Keywords: Antibody-directed enzyme prodrug therapy (ADEPT), cyclic phosphate, cytochrome P450 enzyme, gene-directed enzyme prodrug therapy (GDEPT), N-oxide, nucleoside, oxazaphosphorine, oxime, prodrug, targeted drug delivery
Current Medicinal Chemistry
Title: Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Volume: 15 Issue: 23
Author(s): Kristiina M. Huttunen, Niina Mahonen, Hannu Raunio and Jarkko Rautio
Affiliation:
Keywords: Antibody-directed enzyme prodrug therapy (ADEPT), cyclic phosphate, cytochrome P450 enzyme, gene-directed enzyme prodrug therapy (GDEPT), N-oxide, nucleoside, oxazaphosphorine, oxime, prodrug, targeted drug delivery
Abstract: Cytochrome P450 (CYP) enzymes are a superfamily of heme containing proteins that catalyze xenobiotic metabolism phase I reactions. Oxidation reactions are the most common CYP-catalyzed reactions for both endogenous substrates and exogenous compounds, including drugs, although CYP enzymes are capable also to catalyze reduction reactions. Whereas the majority of clinically used drugs are inactivated by CYPs, several prodrugs are bioconverted to their active species by these enzymes. Therefore, this mechanism could be exploited to a greater extend, e.g. by taking advantage of the different CYP enzymes to achieve targeted drug delivery, to improve efficacy or to decrease the unwanted adverse effects of existing and novel drug molecules. This review describes the potential of CYP enzymes in prodrug design and summarizes a wide variety of CYP-activated prodrug structures, which are on the market or under the development. The bioactivation mechanisms of each CYP-activated prodrug structure are described and the specificity for the different forms of CYP enzymes is discussed.
Export Options
About this article
Cite this article as:
Huttunen M. Kristiina, Mahonen Niina, Raunio Hannu and Rautio Jarkko, Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery, Current Medicinal Chemistry 2008; 15 (23) . https://dx.doi.org/10.2174/092986708785909120
DOI https://dx.doi.org/10.2174/092986708785909120 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design Prevention of Non-communicable Diseases by Balanced Nutrition: Population- specific Effective Public Health Approaches in Developing Countries
Current Diabetes Reviews Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Pathogenesis of SLE Dermatitis - A Reflection of the Process in SLE Nephritis?
Current Rheumatology Reviews Contrast Functions of αA- and αB-Crystallins in Cancer Development
Current Molecular Medicine Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Chemopreventive Properties of Peptide Lunasin: A Review
Protein & Peptide Letters Combined Angiogenic and Osteogenic Factor Delivery for Bone Regenerative Engineering
Current Pharmaceutical Design Cancer Control by Phytochemicals
Current Pharmaceutical Design Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma
Current Molecular Pharmacology Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy
Current Gene Therapy Endogenous Enzyme-responsive Nanoplatforms for Anti-tumor Therapy
Current Drug Targets Cyclosporine A Suppresses the Malignant Progression of Oral Squamous Cell Carcinoma in vitro
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Current Medicinal Chemistry PET-MRI Based Molecular Imaging as a Response Marker in Cervical Cancer: A Systematic Review
Current Molecular Imaging (Discontinued) Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis
Current Cancer Drug Targets Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Molecular Imaging of Neuropsychiatry and Boron Neutron Capture Therapy in Neuro-oncology
Current Molecular Imaging (Discontinued)